Wedbush Issues Optimistic Outlook for Immunome Earnings

Immunome, Inc. (NASDAQ:IMNM) – Equities research analysts at Wedbush boosted their Q1 2025 earnings per share estimates for Immunome in a research report issued to clients and investors on Wednesday, March 19th. Wedbush analyst D. Nierengarten now expects that the company will post earnings of ($0.51) per share for the quarter, up from their prior forecast of ($0.72). Wedbush currently has a “Outperform” rating and a $33.00 price target on the stock. The consensus estimate for Immunome’s current full-year earnings is ($2.21) per share. Wedbush also issued estimates for Immunome’s Q2 2025 earnings at ($0.44) EPS, Q3 2025 earnings at ($0.45) EPS, Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($1.86) EPS, FY2026 earnings at ($1.80) EPS and FY2027 earnings at ($1.35) EPS.

Other equities analysts have also issued research reports about the company. Lifesci Capital assumed coverage on Immunome in a research note on Tuesday, March 11th. They set an “outperform” rating and a $20.00 price target on the stock. Stephens reaffirmed an “overweight” rating and issued a $30.00 target price on shares of Immunome in a research note on Thursday, March 20th. Finally, Guggenheim dropped their price target on shares of Immunome from $35.00 to $25.00 and set a “buy” rating for the company in a research note on Thursday, March 20th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $25.50.

Immunome Stock Performance

NASDAQ:IMNM opened at $6.95 on Monday. The company has a market cap of $604.31 million, a price-to-earnings ratio of -0.86 and a beta of 1.93. The stock’s fifty day moving average price is $9.67 and its two-hundred day moving average price is $11.44. Immunome has a 52-week low of $6.94 and a 52-week high of $26.70.

Immunome (NASDAQ:IMNM) last released its quarterly earnings results on Wednesday, March 19th. The company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.16). The company had revenue of $2.74 million for the quarter, compared to the consensus estimate of $3.07 million. Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%.

Insider Transactions at Immunome

In other Immunome news, CEO Clay B. Siegall acquired 150,000 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The stock was acquired at an average cost of $7.75 per share, for a total transaction of $1,162,500.00. Following the transaction, the chief executive officer now owns 669,636 shares of the company’s stock, valued at $5,189,679. This trade represents a 28.87 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CTO Philip Tsai bought 12,300 shares of the company’s stock in a transaction on Monday, March 24th. The shares were bought at an average price of $8.42 per share, for a total transaction of $103,566.00. Following the completion of the acquisition, the chief technology officer now directly owns 33,300 shares in the company, valued at approximately $280,386. This trade represents a 58.57 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 169,300 shares of company stock worth $1,323,536. 8.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. BNP Paribas Financial Markets bought a new stake in Immunome in the 4th quarter valued at $70,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Immunome in the 4th quarter valued at about $75,000. AlphaQuest LLC lifted its holdings in shares of Immunome by 786,700.0% in the fourth quarter. AlphaQuest LLC now owns 7,868 shares of the company’s stock valued at $84,000 after purchasing an additional 7,867 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Immunome by 482.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company’s stock worth $91,000 after buying an additional 7,129 shares during the period. Finally, Aquatic Capital Management LLC bought a new position in shares of Immunome during the fourth quarter worth about $95,000. Institutional investors and hedge funds own 44.58% of the company’s stock.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.